Ethnic Differences in Reactions to Drugs and Xenobiotics

Proceedings of a Meeting held in Titisee, Black Forest, Federal Republic of Germany, October 3-6, 1985, supported by the Boehringer Ingelheim Fonds

Editors

Werner Kalow
Department of Pharmacology
University of Toronto
Toronto, Ontario, Canada

H. Werner Goedde

and

Dharam P. Agarwal
Institute of Human Genetics
University of Hamburg
Hamburg, Federal Republic of Germany

ALAN R. LISS, INC. • NEW YORK
Contents

Contributors xi

Preface
W. Kalow, H. Werner Goedde, and Dharam P. Agarwal xv

ETHNIC DIFFERENCES IN REACTIONS TO DRUGS AND XENOBIOTICS: INTRODUCTORY INFORMATION

Outlook of a Pharmacologist
W. Kalow 3

Ethnic Differences in Reactions to Drugs and Other Xenobiotics: Outlook of a Geneticist
H. Werner Goedde 9

Genetic Relationship of Human Populations and Ethnic Differences in Reaction to Drugs and Food
Masatoshi Nei and Naruya Saitou 21

Nutrition as an Environmental Influence on Chemical Metabolism in Man
Karl E. Anderson, Allan H. Conney, and Attallah Kappas 39

Problems Perceived in Asia
Gebhard Flatz 55

The Impact of Traditional African Medicine on the Use of Modern Drugs
David T. Okpako 59

Adverse Reactions to Drugs and Metabolic Problems Perceived in Northern Canadian Indians and Eskimos
Otto Schaefer 77

DEFICIENCIES OF DRUG-METABOLIZING ENZYMES

Analysis of the Serum Paraoxonase/Arylesterase Polymorphism in Some Sudanese Families
B.N. La Du, Steve Adkins, and Riad A-L. Bayoumi 87

Ethanol Oxidation: Ethnic Variations in Metabolism and Response
Dharam P. Agarwal and H. Werner Goedde 99
Aldehyde Oxidation: Ethnic Variations in Metabolism and Response
H. Werner Goedde and Dharam P. Agarwal ........................................... 113
Genetic Polymorphism of Mephenytoin Metabolism
T. Inaba ................................................................. 139
Polymorphic Oxidation of Debrisoquine and Sparteine
M. Eichelbaum ......................................................... 157
Slow Hydroxylation of Tricyclic Antidepressants—Relationship to Polymorphic Drug Oxidation
Folke Sjöqvist and Leif Bertilsson ................................................. 169
The Debrisoquine/Sparteine Oxidation Polymorphism: Evidence of Genetic Heterogeneity Among Ghanaians
N.M. Woolhouse ........................................................ 189
Discussion Remarks on the Oxidation Polymorphism
M. Eichelbaum, Folke Sjöqvist, N.M. Woolhouse, Gilbert S. Omenn, N. Matussek, David A. Price Evans, W. Kalow, and Elliot S. Vesell ......... 207
Acetylation
David A. Price Evans .................................................... 209
Conjugation Reactions
W. Kalow ................................................................. 243

DIFFERENTIAL FATES OR ACTIONS OF PARTICULAR DRUGS AND CHEMICALS
The Metabolism and Toxicity of Primaquine
A.H. Price and K.A. Fletcher .................................................. 261
Ethnic Differences in Phenytoin Kinetics
Eigill F. Hvidberg ........................................................ 279
Inter-Individual Variation in the Metabolism of Ethynylestradiol
B.K. Park and J.L. Maggs .................................................. 289
Relevance of Polymorphic Drug Oxidation in the Use of Neuroleptics in Schizophrenia
Siu W. Tang ................................................................. 303
Antihypertensive Agents
Edward D. Freis ........................................................... 313
Clioquinol
F. Clifford Rose ........................................................... 323
Caffeine and Other Drugs
W. Kalow ................................................................. 331

PROTEIN VARIANTS OF REALIZED OR POTENTIAL PHARMACOGENETIC EFFECTS
Other Protein Variants With Pharmacogenetic Consequences: Albumin and Orosomucoid
Gunnar Alván ................................................................. 345
Receptor and Binding Proteins in Endogenous Psychoses
N. Matussek and B. Bondy ............................................. 357

Receptor Variation as a Source of Differential Response to Centrally Acting Agents: Phylogenetic Evidence
Johannes Hebebrand, Waltraut Friedl, Klaus-Ulrich Lentes, and Peter Propping ............................................. 367

Clinical and Molecular Studies of Alpha1-Antitrypsin Deficiency
Diane Wilson Cox .......................................................... 373

Glucose-6-Phosphate Dehydrogenase and Other Genetic Factors Interacting With Drugs
Lucio Luzzatto .............................................................. 385

Metallothionein Deserves Attention
Monica Nordberg .......................................................... 401

ASSESSMENT OF POPULATIONS: PROBLEMS OF METHODOLOGY
The Detection of Polymorphic Drug Oxidation—Some Theoretical and Practical Aspects
G.T. Tucker, P.R. Jackson, M.S. Lennard, and H.F. Woods .......................................................... 413

Dynamic Interactions Among Host Factors that Influence Antipyrine Metabolism: Implications for the Design and Interpretation of Studies on Ethnic Pharmacokinetic Variations
Elliot S. Vesell .............................................................. 425

Current Cellular Assays for Measuring Clinical Drug Metabolizing Capacity—Impact of New Molecular Biologic Techniques
Richard E. Kouri, Theodore McLemore, Anil K. Jaiswal, and Daniel W. Nebert ............................................. 453

Standardization of Mice by Litter Adjustment and the Use of the 14-CO2 Exhalation to Assess Drug Metabolising Capacity in Rats
Karl J. Netter, Friedrich Heubel, and Christian Steffen .......................................................... 471

The Molecular Map of the Human Genome as a Basis for the Study of Ethnic Differences in Reactions to Xenobiotics
Karl-Heinz Grzeschik .......................................................... 479

IMPLICATIONS AND CONSEQUENCES
Therapy
D.A. Price Evans .......................................................... 491

Susceptibility to Occupational and Environmental Exposures to Chemicals
Gilbert S. Omenn .......................................................... 527

Panel Discussion
Chairman: W. Kalow .......................................................... 547

SUMMARY AND CONCLUDING REMARKS
Summing Up
Gilbert S. Omenn .......................................................... 563

Index .......................................................... 567